There is increasing evidence that affective disorders are associated with dysfunction of neurotransmitter postsynaptic transduction pathways and that chronic treatment with clinically active drugs results in adaptive modification of these pathways. Despite the close dependence of signal transduction on adenosine triphosphate (ATP) availability, the changes in energy metabolism in affective disorders are largely unknown. This question has been indirectly dealt with through functional imaging studies (PET, SPECT, MRS). Despite some inconsistencies, PET and SPECT studies suggest low activity in cortical (especially frontal) regions in depressed patients, both unipolar and bipolar, and normal or increased activity in the manic pole. Preliminary MRS studies indicate some alterations in brain metabolism, with reduced creatine phosphate and ATP levels in the brain of patients with affective disorders. However, the involvement of the energy metabolism in affective disorders is still debated. We propose direct neurochemical investigations on mitochondrial functional parameters of energy transduction, such as the activities of (a) the enzymatic systems of oxidative metabolic cycle (Kreb's cycle); (b) the electron transfer chain; (c) oxidative phosphorylation, and (d) the enzyme activities of ATP-requiring ATPases. These processes should be studied in affective disorders and in animals treated with antidepressant drugs or lithium. Keywords: bipolar disorders; major depression; antidepressants; intracellular signaling; brain energy metabolism Despite the efficacy of antidepressant drugs (ADs) and decades of use, the mechanism underlying their therapeutic action is still open to debate. Confounding issues are: (a) the time lag between the primary pharmacological effects (hours) and the onset of therapeutic effects (weeks), and (b) the different mechanisms of action of various classes of ADs. Increases in intra-or extrasynaptic norepinephrine (NE) and/or serotonin (5-HT) levels induced by acute AD treatment appear to be the triggering events, while the therapeutic effect is produced by an adaptive response of the central nervous system (CNS) to chronic treatments, that is, substantial and longlasting perturbations in neural function mediated by the initial targets.
Despite the efficacy of antidepressant drugs (ADs) and decades of use, the mechanism underlying their therapeutic action is still open to debate. Confounding issues are: (a) the time lag between the primary pharmacological effects (hours) and the onset of therapeutic effects (weeks), and (b) the different mechanisms of action of various classes of ADs. Increases in intra-or extrasynaptic norepinephrine (NE) and/or serotonin (5-HT) levels induced by acute AD treatment appear to be the triggering events, while the therapeutic effect is produced by an adaptive response of the central nervous system (CNS) to chronic treatments, that is, substantial and longlasting perturbations in neural function mediated by the initial targets. 1 Therefore, the original 'biogenic amine hypothesis', based on acute increases in NE and 5-HT levels, has been revised to include changes in downregulation (reduced number) and desensitization (diminished responsiveness) of some pre-and postsynaptic NE and 5-HT receptors. However, opinions differ on the effects of some tricyclic ADs and of electroconvulsive shock (ECS) on receptors. Overall, there is no convincing data suggesting that changes in monoaminergic receptors play a direct role in the therapeutic response to chronic ADs. 1, 2 However, a large body of evidence now indicates that: (a) affective disorders are associated with alterations in the intracellular signal transduction pathways mediating the action of NE or 5-HT receptors, (b) long-term AD and lithium treatments result in adaptive phenomena stemming from the activation of these pathways.
Although it is beyond the aim of this review to analyze the complex signaling pathways that are a common feature of G-protein-coupled receptor families, a brief overview is provided of the molecular mechanisms involved in transmembrane postsynaptic signal transduction, which are relevant to the cellular and molecular theory of affective disorders (reviewed in Racagni et al, 3 Manji, 4 Warsh and Li, 5 Duman et al, 6 Popoli et al, 7 Perez et al, 8 Manji et al, 9 Lenox et al 10 ).
The signal transduction cascades
Stimulation of membrane receptors by neurotransmitters triggers a variety of intracellular signaling cascades mediated by second messengers (Figure 1 ).
Neurotransmitter-stimulated postsynaptic receptors are coupled to intracellular effectors via a family of heterotrimeric G proteins, so named because their function is regulated by binding of guanyl nucleotides (GTP/GDP). Since almost all monoamine receptors are linked to G proteins, they have the critical role of acting as transducers of information across plasma membranes. G proteins are composed of three subunits: a, which binds and hydrolyzes GTP and plays a major role in G protein specificity; b and g. 11 Their action requires adenosine triphosphate (ATP) for the resynthesis of GTP.
Once a G protein has been activated, it can regulate one or more types of membrane effectors, that is, the enzymes catalyzing the synthesis of second messengers. Gs (stimulatory) and Gi (inhibitory) proteins participate in the synthesis of cyclic adenosine monophosphate (cAMP) from ATP in a reaction catalyzed by the enzyme adenylyl cyclase, which is most abundant in the brain. Adenyl cyclase is stimulated by the a unit of Gs (Gas), but inhibited by Gi. 12, 13 The responses following activation of b-adrenergic receptors stem from Gs-mediated stimulation of adenylyl cyclase. Conversely, a 2 -adrenergic autoreceptors and 5-HT 1 receptors are negatively coupled to adenylyl cyclase through Gi; cAMP action is terminated by the enzyme phosphodiesterase that hydrolyzes cAMP to inactive AMP.
Other G proteins (Gq) stimulate the activity of phospholipase C 14, 15 : a 1 -adrenergic, 5-HT 2 , and muscarinic cholinergic receptors act through this mechanism. Phospholipase C hydrolyzes phosphoinositides (a class of membrane phospholipids) to the second messengers diacylglycerol and inositol 1,4,5-triphosphate. The latter undergoes dephosphorylation by phosphatases, producing inositol, which is rephosphorylated to phosphoinositides by consuming various molecules of ATP.
Inositol 1,4,5-triphosphate and diacylglycerol have different functions: the first leaves the plasma membrane and enters the cytoplasm where it stimulates the release of Ca 2 þ ions, particularly from endoplasmic reticulum storage granules. Ca 2 þ ions activate Ca 2 þ -dependent processes, for example, the conversion of Ca 2 þ -dependent protein kinase CaM-K II (see below) from inactive to active forms. Diacylglycerol remains in the membrane and stimulates the activity of protein kinase C (see below).
In this context, the proposed mechanism of action of lithium is noterworthy. Within a few days of treatment and at therapeutically relevant brain concentrations (E0.5-0.8 mM), lithium inhibits inositol monophosphatase. This raises the brain level of inositol monophosphate and depletes myo-inositol, thereby compromising phosphoinositide resynthesis and attenuating the receptor responses to NE, 5-HT, and acetylcholine ('inositol depletion hypothesis'). However, considering the complexity of lithium's clinical action and the effects on mood, the mechanism is likely to be more complex, involving multiple steps. 9, 10, 16 The second messengers operate by activating third messengers, the protein kinases, 6 which catalyze the phosphorylation of various proteins, thereby modifying their conformation, and consequently their biological activity. These reactions involve the consumption of several molecules of ATP. The phosphoproteins' action is terminated by protein phosphatases, which convert them to inactive dephosphoprotein. There are various protein kinases:
1. The Ca 2 þ /calmodulin-dependent protein kinase II is the most abundant in the brain 17 (in presynaptic terminals and postsynaptic densities). It mediates the responses to changes in intracellular Ca 2 þ concentrations by phosphorylating the vesicular proteins synapsin I and synaptotagmin (thereby stimulating neurotransmitter release), some receptors and microtubule-associated proteins (MAPs). 2. The cAMP-dependent protein kinase, 18 is a central constituent of the cAMP signaling system, and is present at high concentrations in the brain. The inactive tetramer enzyme contains a regulatory (R) dimer and two active catalytic (C) subunits. When the level of cAMP rises, it binds to R subunits and brings about conformational changes of the enzyme, dissociation of the tetramer and the release Figure 1 The intracellular signalling cascades. 19 3. Finally, protein kinase C is a family of phosphorylating enzymes activated by Ca 2 þ and diacylglycerol, connected with the phosphoinositide system. 20 Under basal conditions, protein kinase C is located in the cytoplasm. Once activated, the enzyme shifts to the plasma membrane, the site of many of its substrates, including receptors and ion channels. Essential in the processes of translocation and activation is the receptor for activated kinase 1 (RACK1), which interacts with protein kinase C and anchors it to the membrane. 21 In summary, neurons possess a biochemical machinery that controls the generation, degradation and biological response of second and third messengers composed of G proteins, adenylyl cyclase or phospholipase C, and protein kinases. Most of these processes require metabolic energy, consuming many molecules of ATP as the donor of phosphate groups.
With regard to clinical and experimental data, Tables 1 and 2 summarize the main differences in post-mortem brain areas of affective disorder patients compared to controls. Table 3 shows the results of experimental studies on the effects of ADs and lithium on signaling cascades in the rat brain, and Table 4 reports the changes in energy-rich compounds.
Changes in intracellular signaling cascades in affective disorders and after treatment with ADs or lithium
Results in patients are far from unequivocal, either because of the heterogeneous clinical and therapeutic situations of the patients at death, or the experimental conditions of the studies. The overall results suggest that:
1. Bipolar Disorder (BD) ( Table 1 ) is associated with: [22] [23] [24] [25] [26] [27] [28] [29] [30] (a) enhanced signal transduction in the cAMP cascade as shown by higher levels of Gas protein, stimulated adenylyl cyclase and cAMPdependent protein kinase, (b) hyperactivity in the phosphoinositide system as indicated by the rise of G protein coupled to phospholipase C, protein kinase C activity and its association with RACK1. Various peripheral cells also show enhanced Gas and its expression, and increased protein kinase C activity and phosphatidylinositol-4,5-biphosphate levels, especially during the manic state. [31] [32] [33] [34] [35] [36] [37] [38] At variance with these data, a region-selective impairment of phosphoinositide hydrolysis was reported in the occipital cortex. 29 The reduction of cAMP binding 26 due to a decrease in the R subunits of cAMP-dependent protein kinase may actually increase kinase activity and protein phosphorylation at subsaturating cAMP concentrations.
In keeping with these findings, lithium appears to affect second messenger systems, as indicated by the decrease in: (a) b-adrenergic and cholinergic agonist-induced GTP binding to G proteins, (b) b-adrenergic-coupled adenylyl cyclase activity, (c) cAMP-dependent protein kinase A-and protein kinase C-regulated protein phosphorylation (see also  Table 3 ), and (d) by the modulation of crosstalk between protein kinase C and the cAMP generating system. 39 In BD patients, lithium also reduced Gas, and the anticonvulsants sodium valproate and carbamazepine reduced CREB (Table 1) . The observation that multiple sites are involved in the action of lithium firmly suggests that its outcome is the result of a balance between various modulatory effects, rather than a single mechanism. 9, 10, 16 2. In contrast, patients with Major Depression (MDD) ( Table 2) showed enhanced Gai (the inhibitory G protein a subunit), unchanged Gas and reduced adenylyl cyclase in various cortical areas, suggesting an imbalance between stimulatory and inhibitory functions, in favor of the latter. 24, 25, [40] [41] [42] [43] [44] [45] Similar results were obtained in peripheral cells. cAMP-dependent protein kinase activity was lower in skin fibroblasts of depressed patients than in normal volunteers, 46, 47 and the platelets of untreated unipolar patients had lower levels of the RII subunit of PKA and of RAP1 (a substrate of the kinase) than either euthymic patients or healthy subjects. 48 Studies comparing the changes in untreated or AD-treated MDD patients have given conflicting results ( Table 2 ). The concentration of CREB in the cortex was higher, 44 but cAMP binding was lower 43 in AD-treated patients than untreated ones. Tricyclic ADs also raised protein kinase C in platelets. 49 In rats, chronic administration of ADs increased various upstream and downstream processes of cAMP signaling, including CREB expression and protein phosphorylation [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] (Table 3) . Some of these effects were found in microtubules after 2-week treatment, but after 3 weeks in cytosol, suggesting that the adaptive events set in motion by ADs imply translocation between specific intracellular compartments, therefore different functions. Various protein kinases (Ca 2 þ -calmodulin-dependent protein kinase, PKA and two serine/threonine kinases) were also activated by ADs.
Therefore, although there is no convincing evidence that depression is related to monoamine deficit or receptor alterations, there is growing agreement about a dysfunction of the signal transduction from monoamine neurotransmitters to their postsynaptic neurons and a mechanism of AD activity based on the reversal of this dysfunction.
The phosphorylating enzymes are one site of AD activity. When they are activated, this stimulates the transfer of phosphate from ATP into selected substrates, therefore the consumption of brain energy stores (ATP). Other studies point to the role of CREB as a critical transcription factor in the adaptive responses to ADs. 65, 66 One gene target that is upregulated by CREB and that could be involved in the pathophysiology of depression and in the mechanism of action of ADs and electroconvulsive seizures is brainderived neurotrophic factor (BDNF). Recent experimental studies support the hypothesis that stress may reduce BDNF expression in the hippocampus, thus leading to the atrophy, or even death, of hippocampal vulnerable neurons. 6 Chronic stress or glucocorticoid administration in animals induce degeneration of specific hippocampal neurons, and stress-mediated alterations of the hippocampus have been proposed as major factors contributing to the onset of depression in genetically vulnerable subjects. 67 However, the hippocampus is only one of the few brain regions where neurogenesis occurs in various adult mammalian species including humans. 68 These findings are relevant in the light of: (a) neuroimaging [69] [70] [71] and histopathological evidence 72 that, at least in certain patients, affective disorders are accompanied by volume reduction and morphological changes (loss, atrophy) of neurons and glial cells in various brain regions, particularly the hippocampus and the prefrontal and orbitofrontal cortices, (b) the possibility that impaired neurogenesis could play a role in these alterations (reviewed in Soares and Mann, 73 Manj et al.
74
). It is not surprising, therefore, that chronic treatment with different classes of ADs (but not with other psychotropic drugs) prevented the stress-induced reduction of neurogenesis in the rat hippocampus. [75] [76] [77] Consistent with these effects, chronic ADs reversed the downregulation of BDNF and increased its expression and that of its receptor trkB. 78 BDNF itself had antidepressant-like effect in two animal models of depression. 79 Thus, ADs appear to regulate indirectly a number of factors involved in neuroplasticity, and may induce some of their delayed beneficial effects through neurotrophic action. 72, 78 Their mechanism of action may therefore affect gene expression, an effect that is the farthest of those proposed so far from neurotransmitters and receptors (see Figure 1 ).
Treating rats with lithium, rather than ADs, reduced most components of the signal transduction cascade. [80] [81] [82] [83] [84] [85] [86] [87] [88] (Table 3 ). PKC appears to mediate the action of lithium and also of carbamazepine and valproate. Their chronic administration to rats results in significant decreases of two isozymes of the PKC family (a and e). Although the mechanism of this specific effect of lithium is not clear, it might be related to the subtle differences between the biochemical characteristics and susceptibility of the different isozymes. 9 Consistent with the 'inositol depletion hypothesis' of lithium's mechanism of action, the downregulation of the e isozyme of PKC is reversed by myo-inositol. 89 Finally, the activity of Ca 2 þ -calmodulin-dependent protein kinase, its affinity for ATP and the phosphorylation of its substrates in the cortex and hippocampus were enhanced by long-term treatment with various ADs, but reduced by lithium.
Energy metabolism in signaling cascades
We find it surprising that the extensive literature on the dysfunction of signaling cascades in affective disorders and on AD effects does not consider energy. This information would be important because numerous molecules of ATP are needed for G-protein functioning, cAMP formation, PI resynthesis, protein kinase activities, various events at the synapse (transport of ions and neurotransmitter uptake), and protein synthesis.
This last process is fundamental to the mechanism of ADs, whose action is related to changes in the levels of various enzymes and, possibly, neurotrophic factors and neurogenesis. One molecule of ATP is required for the formation of a peptide bond, corresponding to a DG ¼ À7.5 kcal/mol. Thus, the synthesis of a protein of n amino acids requires the consumption of nÀ1 molecules of ATP, just to activate each amino acid. If, for example, n is equal to B1100-1200 (as in the case of AC and PLC) the synthesis of every molecule of these enzymes consumes a large amount of ATP. Therefore, any changes caused by pathological conditions or pharmacological treatments will affect the biochemical events regulating ATP synthesis and metabolism, even more so when both second messenger systems are involved.
Among the pathophysiological conditions affecting signaling processes, brain hypoxia/ischemia is the most striking, because it reduces the availability of ATP. In experimentally induced hypoxia in rats (PaO 2 o20 mmHg), the stimulation of AC by b-adrenergic agonists does not lead to cAMP synthesis because of the lack of ATP; therefore cAMP loses its ability to function as a regulatory factor. 90 The essential concepts of brain energy metabolism will now be summarized as an introduction to the neuroimaging section of this review.
Cerebral energy transduction systems
The CNS is metabolically one of the most active organs in the body, since it accounts for only 2% of body weight but about 20% of resting total body O 2 consumption and 25% of glucose. O 2 is utilized almost entirely for glucose oxidation. The resulting energy is transferred for the synthesis of 'high-energy phosphate' bonds (ATP). Only 40% of the energy released from glucose can be used for metabolic pathways since about 60% is lost as heat and entropy. Therefore, the efficiency of the energy transducing pathways is low.
Neuronal activity is closely coupled to energy metabolism which is mainly used for the active transport of molecules and ions that sustain the membrane potentials discharged during excitation and conduction. The energy requirement is particularly high for Na þ , K þ -, Ca 2 þ -, and other ATPases in plasma and endoplasmic membranes.
In most energy-consuming processes, the free energy donor is ATP, an energy-rich molecule that owes this feature to two phosphoanhydride bonds. A large amount of free energy is released when ATP is hydrolyzed to adenosine diphosphate (ADP) and orthophosphate (P i ), or adenosine monophosphate (AMP) plus pyrophosphate (PP i ). In both reactions, the standard free energy change (DG1 0 ) is -7.3 kcal/ mol. The brain concentration of ATP is low (B2 mM), but its turnover is very high. Therefore, the possibility of the adenylate system acting as an energy mediator depends closely on the rate of ATP resynthesis: (a) from other 'high-energy phosphates', such as creatine phosphate (CP), a reservoir of high-energy phosphoryl groups that can be readily transferred to ATP through the reaction catalyzed by the enzyme creatine kinase; (b) through anaerobic glycolysis in the cytosol, a sequence of reactions converting glucose into pyruvate with net generation of two molecules of ATP from ADP for each molecule of glucose; (c) through aerobic mitochondrial processes in the tricarboxylic acid (TCA) cycle, the final pathway of pyruvate oxidation to CO 2 and H 2 O with the synthesis of ATP from ADP þ P i by oxidative phosphorylation, the major source of ATP.
ATP is formed by oxidative phosphorylation during the electron transfer from pyridine (NADH) or flavin (FMNH 2 , FADH 2 ) coenzymes (generated in the TCA) to O 2 by a series of electron carriers, including coenzyme Q and cytochromes (a, b, c). The net yield of high-energy phosphate bonds in ATP formed by complete oxidation of one molecule of glucose to CO 2 and H 2 O is 38 molecules.
ATP synthesis thus stems from the concerted action of the following metabolic systems operating in the mitochondria: (a) an electron-donor generating system, that is, the intermediates of TCA; (b) a system of carriers for the transport of electrons to O 2 , the electron transfer chain (ETC); (c) a system for the synthesis of ATP from ADP þ P i using the free energy resulting from the flow of electrons from NADH or succinate to O 2 , a highly exergonic process.
To sum up, the ETC releases a large amount of free energy converted into the chemical energy of ATP during phosphorylation in mitochondria. Mitochondria also play a major role in (a) regulating cellular free Ca 2 þ which they can accumulate when its concentration rises above critical values, (b) controlling glycolysis and the activity of Na þ , K þ -and Ca 2 þ -ATPases of plasma membrane and the activity of Na þ -coupled plasma membrane transporters. Methodologically, energy metabolism in brain samples can be studied by three different, albeit closely related, approaches:
1. determination of the adenylate pool constituents (ATP, ADP, AMP), CP, and the relevant intermediates of glycolysis and TCA; 2. assessment of oxidative phosphorylation, ETC complexes, TCA enzymes, Na þ , K þ -ATPase, Ca 2 þ -ATPase, and other ATPases; 3. establishing the ADP : O ratio.
Besides classical biochemical methods, various other methods have been devised to study the brain metabolism in humans in vivo, applying functional neuroimaging techniques. Positron emission tomography (PET) provides clues to the glucose metabolism by measuring the uptake of 18 [F]fluorodeoxyglucose (FDG), a glucose analog actively transported into neural cells. By measuring the H 2
15
O uptake, PET also analyzes cerebral blood flow (CBF), providing an indirect measure of cerebral metabolism. CBF can also be investigated by single-photon emission computed tomography (SPECT) using 133 xenon or 99 technetium-containing compounds, hexamethylpropylene aminoxime ( FDG uptake is generally considered an assay of 'energy metabolism'. As a matter of fact, FDG only undergoes the first step in glycolysis, phosphorylation to FDG-6-phosphate which, unlike glucose-6-phosphate, is not further metabolized and accumulates in cells. Therefore, as stated by Phelps.
91 the trapped FDG-6-phosphate provides a record of glycolysis in cells which is coupled to neuronal activity. The 'energy metabolism', or more specifically, 'energy transduction', is a far more complex process.
At variance with the conventional view that glucose is the main substrate for neuronal energy metabolism, Magistretti and Pellerin 92 points to a possible role of lactate as substrate and of astrocytes and glutamate as 'pivotal elements in the coupling of synaptic activity with energy metabolism'. In this context, PET might, at least in part, reflect the uptake of FDG by astrocytes. However, there is still no evidence that neurons utilize glial-produced lactate as their main energy substrate during activity. 93 
Neuroimaging in affective disorders, and therapy
There is considerable debate about whether functional imaging abnormalities of FDG uptake and CBF are present in affective disorders. [94] [95] [96] [97] [98] The regions most commonly affected in MDD were the prefrontal cortex, anterior cingulate gyrus, and temporal lobe, with contrasting results in subregions of these areas: Is brain energy metabolism involved in effective disorders? A Moretti et al 1. decreases in the dorsomedial, lateral and dorsolateral prefrontal cortex, dorsal anterior cingulate cortex, and hippocampus; 2. increases in the left ventrolateral prefrontal, subgenual prefrontal cortex (after correcting for volume reduction 99 ), amygdala, and thalamus. The amygdala is the only brain region where the abnormalities of FDG uptake and CBF correlated with the severity of the depression (Hamilton scale). 100 Some alterations tended to return to normal during treatment with tricyclic ADs (desipramine, nortryptyiline), various SSRIs (paroxetine, sertraline, fluoxetine), or sleep deprivation. The activity in the ventrolateral prefrontal and orbital cortices decreased in the remitted phase compared with the depressed phase. [101] [102] [103] [104] [105] [106] However, results in the anterior cingulate were variable. 102, [106] [107] [108] [109] [110] . A further development in PET studies is the attempt to correlate metabolic abnormalities in brain regions with different symptoms of MDD. The clinical improvement induced in various clusters of MDD symptoms by treatment with paroxetine or psychotherapy was associated with changes of FDG uptake in specific brain regions. 111 The improvements in symptoms of anxiety/somatization and of depressed/sad mood/psychomotor retardation were strongly associated with lower FDG uptake, respectively, in the left and right ventral frontal lobes.
Only one experimental study has looked into the effects of ADs on deoxyglucose uptake in animals. Using the autoradiographic [
14 C]deoxyglucose procedure, which evaluates regional metabolic rates for glucose (rCMRglc), this study showed that single doses of chlorimipramine (CMI) reduced rCMRglc in a number of rat brain regions with high density of 5-HT uptake sites. 112 The elimination of these effects by pretreatment with a 5-HT neurotoxin confirmed that CMI acted through a presynaptic mechanism. 113 There are no reports on the effects of chronic treatment with CMI or other ADs.
Findings in BD are less consistent. PET studies reported lower FDG uptake in the prefrontal and temporal cortex and higher uptake in the occipital cortex of depressed patients compared to healthy subjects, whereas in manic patients, the reverse pattern was less clear. SPECT studies suggested lower CBF in the frontal and temporal cortex in BD patients, particularly in the left hemisphere. 94 A SPECT study of lithium in euthymic BD patients showed that its withdrawal was associated with redistribution of brain circulation, with an increase in posterior perfusion and decrease in frontal perfusion. One study showed the correlation between the development of mania after lithium withdrawal in some subjects and increased perfusion of the superior anterior cingulate. 114 However, information on this particular effect of the treatment is still insufficient.
Overall, the considerable PET and SPECT literature suggests that the frontal cortex is hypoactive during depression, whether unipolar or bipolar. 96 PET and SPECT provide an indirect assessment of metabolic brain activity. As previously pointed out, more direct information about the brain energy metabolism can be obtained by measuring brain metabolism in vivo, such as the 'high-energy phosphates' (ATP and CP), with 32 P and 1 H MRS. These studies (reviewed in Kato et al, 115 Moore and Renshaw, 116 Renshaw et al 117 ) brought to light a variety of dysfunctions (Table 4) . [118] [119] [120] [121] [122] [123] [124] [125] [126] 1. In MDD, the concentration of CP was lower in the severe than in the mild group. This implies that alterations in energy metabolism might be related to the severity of depression, an assumption supported by the PET and SPECT studies. ATP was lower in depressed patients than controls. Interestingly, a recent MRS study found that the levels of purines (mainly ATP) were lower in fluoxetine-responder MDD patients than in nonresponders, suggesting that the 'response to treatment may be predicted by the result of MRS' and 'agents that increase the brain levels of ATP may have antidepressant efficacy'. 117 2. In BD, CP was consistently decreased in depressive, euthymic, and manic states. CP levels were asymmetrical in medicated patients: they were lower in the left than in the right frontal lobe in the depressive state and the reverse in euthymic and manic states. This result was not replicated in a subsequent study in which patients were washed out for 1 week before examination.
The assay of CP in the occipital cortex of subjects undergoing photic stimulation provides further insight into energy metabolism alterations in BD. In normal subjects, this level declines because of increased energy demand and CP consumption. 127 In BD, however, CP is further decreased in lithiumresistant patients but not in responders. 121 Intracellular pH was lower in either lithium-treated or drug-free euthymic BD patients than in controls, but was normal in manic and depressive states. There are two possible explanations for the lower pH in euthymic patients: either an increase of lactate or abnormal Na þ /K þ exchanger activity. 115 So far there have been no investigations of brain lactate concentration in BD, but a decrease in Na þ , K þ -ATPase activity was reported in the erythrocytes of both manic and depressed bipolar patients compared to euthymic ones. 128 Thus, Kato et al. 115 speculated that in BD the alteration of monoaminergic systems, possibly through hypersensitivity due to changes in signal transduction, might be the result of the compensatory mechanisms of these systems to right the low pH. Although very speculative, this theory could help account for the pH found in the various states of BD.
Another biochemical parameter that has been measured by 1 H MRS studies in the brain is 74, 129 NAA is synthesized within the mitochondria and inhibition of each of the four complexes of the mitochondrial electron transfer chain results in a decrease of NAA synthesis correlated with a decline in ATP synthesis and O 2 consumption. 130 Recent findings of low NAA concentrations in the dorsolateral prefrontal cortex 131 and in the hippocampus. 132 of BD patients provide indirect evidence of a possible energy metabolism dysfunction in affective disorders.
In view of the limited number and the inconsistencies in the studies on high-energy compounds, it is impossible to reach any firm conclusion, apart from a general impression of 'energy distress'. More investigations with the MRS technique are needed.
A factor contributing to energy impairment in depression, at least in elderly patients, might involve the cardiovascular or cerebrovascular changes leading to brain hypoxia. Indeed, the link between relative cerebral hypoperfusion and depression in elderly cardiac patients has been reported, 133 and the presence of small lesions in the basal ganglia was associated with depressive symptoms in a large geriatric population. 134 An even more preliminary area of investigation involves the effects of ADs on energy transduction in the rodent brain. Repeated administration of imipramine significantly increased mitochondrial respiration and the content of cytochromes b, c þ c 1 and aa 3 . 135 A single dose of desipramine significantly enhanced Na þ , K þ -ATPase in synaptosomal membranes of rat hypothalamus and mesencephalus. 136 This effect persisted up to 21 days after treatment. 137 Unfortunately, there are no other studies on the effects of ADs or lithium on energy metabolism in animals. It is noteworthy that after oral or intravenous administration to rats, 40% of fluoxetine concentrated in mitochondria plus synaptosomes, 138 thus making these subcellular fractions a possible site of action of the drug.
Conclusions
It is generally accepted that the pathogenesis of affective disorders and the therapeutic effects of ADs are related to adaptive mechanisms of neurotransmitter systems, probably the intracellular signaling cascades consisting of second and third messengers which eventually mediate the physiological responses. The involvement of long-lasting events (ie regulation of gene expression: see Figure  1 ) has also now been convincingly argued. All these processes, especially those involving de novo protein synthesis (eg the synthesis of enzymes, neurogenesis) and phosphorylation, closely depend on energy metabolism, requiring even considerable amounts of ATP. However, the involvement of energy transduction in affective disorders and in the action of drugs has not been directly explored, unlike hypoxiaischemia (reviewed in Villa and Gorini 139 ). The only available evidence, although indirect, that energy transduction processes are implicated in the pathogenesis of affective disorders and the action of drugs comes from neuroimaging studies on FDG uptake and CBF and from the limited, and not always concordant, MRS studies on high-energy compounds, mainly creatine-phosphate and on N-acetylaspartate. Consistent with this interpretation are the changes in cerebrovascular/cardiovascular function that could lead to hypoxic episodes in some brain regions.
These studies indicate a dysfunction of mitochondrial energy transduction in patients with affective disorders, possibly involved in the pathogenesis. This is supported by the alterations (mutations/polymorphisms) of mitochondrial DNA (mtDNA) in the brain of BD patients. 140, 141 According to Kato and Kato, 142 in BD the decreased Ca 2 þ buffering capacity of mitochondria might result in an enhanced agonistinduced intracellular calcium response and hypersensitivity to monoaminergic systems. Although intriguing, this hypothesis clearly requires further study. Among other inconsistencies, the high-energy compounds are apparently decreased in both BD (in all three states) and MDD, and only euthymic bipolar patients show lower pH. Furthermore, the effects of ADs or lithium on energy transduction have not been investigated. It might therefore be more reasonable to conclude that the energy transduction processes are somewhat altered in affective disorders, possibly even reaching a state of 'energy distress'. If this is the case, pharmacological treatments should try to restore a normal energy situation, as indirectly suggested by some neuroimaging studies.
Paths for future research
If affective disorders actually were potential energydeficiency syndromes, the experimental approach should be to study cerebral energy transduction processes at several levels. Ideally, these should include: (a) affective disorder patients; (b) appropriate animal models of depression; (c) drug-treated animals. Careful, methodical investigations should focus on the enzyme activities of the TCA and ETC complexes in mitochondria (especially in various mitochondrial populations with different characteristics), 143 and the activities of Na þ , K þ -ATPase, Ca 2 þ -ATPase, and other ATPases. 144 Current technologies [143] [144] [145] [146] [147] [148] make these advanced studies possible even in small samples of cerebral tissue from animals or humans.
